Inhibition of miR-133b indicates poor prognosis and promotes progression of OSCC via SOX4.
CONCLUSIONS: MiR-133b was lowly expressed in OSCC tissues and cell lines. Down-regulation of miR-133b reduced the proliferation, invasion and migration of OSCC cells via regulating SOX4. All our findings suggested that miR-133b could be used as a potential target for the treatment of OSCC.
PMID: 33378019 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Oral Cancer | Skin Cancer | Squamous Cell Carcinoma | Study